for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TrovaGene Inc

TROV.OQ

Latest Trade

1.71USD

Change

0.05(+3.01%)

Volume

27,554

Today's Range

1.66

 - 

1.74

52 Week Range

1.37

 - 

9.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.66
Open
1.68
Volume
27,554
3M AVG Volume
6.09
Today's High
1.74
Today's Low
1.66
52 Week High
9.64
52 Week Low
1.37
Shares Out (MIL)
6.18
Market Cap (MIL)
10.57
Forward P/E
-0.49
Dividend (Yield %)
--

Next Event

Q3 2019 Trovagene Inc Earnings Release

Latest Developments

More

Trovagene Announces Successful Completion Of Phase 1B Trial Of Onvansertib In Acute Myeloid Leukemia And Initiation Of Patient Enrollment In Phase 2

Trovagene Says Qtrly Loss Per Share $0.79

Trovagene Files For Mixed Shelf Of Up to $150 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TrovaGene Inc

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

Industry

Healthcare Facilities

Contact Info

11055 Flintkote Ave

+1.858.9527570

https://trovageneoncology.com/

Executive Leadership

Thomas H. Adams

Chairman of the Board, Interim Chief Executive Officer

Athena M. Countouriotis

Director

Paul R. Billings

Independent Director

John P. Brancaccio

Independent Director

Gary S. Jacob

Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-91.440

2017

-51.840

2018

-8.260

2019(E)

-3.515
Price To Earnings (TTM)
--
Price To Sales (TTM)
22.66
Price To Book (MRQ)
1.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-111.12
Return on Equity (TTM)
-89.56

Latest News

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Trovagene Reports Q4 Loss Per Share $0.06

* TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Prices $4.5 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 15 MILLION SHARES OF ITS COMMON STOCK, COMMON WARRANTS TO PURCHASE UP TO 15 MILLION SHARES OF COMMON STOCK

BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®

* TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Inc updates on clinical trial for PCM-075

* Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075

BRIEF-TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12

* AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS Source text: (http://bit.ly/2hgteK4) Further company coverage:

BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing

* Trovagene Inc files for offering of up to $17.5 million - SEC filing Source text: (http://bit.ly/2zOQs1P) Further company coverage:

BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga

* Trovagene Inc - announced positive data from preclinical research demonstrating synergy of PCM-075 in combination with abiraterone (Zytiga)

BRIEF-Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075

* Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML)

BRIEF-Trovagene files for offering of upto sale 4.64 mln shares of common stock by the selling stockholders

* Trovagene Inc files for offering of up to sale 4.64 million shares of common stock by the selling stockholders - SEC Filing Source text: (http://bit.ly/2fELxf1) Further company coverage:

BRIEF-Trovagene appoints Athena Countouriotis to its board of directors

* Trovagene strengthens board of directors with appointment of oncology development veteran Dr. Athena Countouriotis Source text for Eikon: Further company coverage:

BRIEF-Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor

* Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy

BRIEF-Trovagene Q2 loss per share $0.26

* Trovagene announces second quarter 2017 company highlights and financial results

BRIEF-Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

* Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

BRIEF-Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with PCM-075

* Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with pcm-075, its polo-like kinase 1 (plk1) inhibitor

BRIEF-CVI Investments Inc reports 5.7 percent passive stake in Trovagene as of July 13 - SEC filing

CVI Investments Inc. Reports 5.7 Pct Passive Stake In Trovagene Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up